News & Updates

Treatment with semaglutide yields early and sustained improvements in multiple atherosclerotic cardiovascular disease (ASCVD) factors in high-risk patients with type 2 diabetes (T2D) and ASCVD and/or chronic kidney disease (CKD), according to a post hoc analysis of the SOUL trial.

Supplementation with anthocyanin improves insulin sensitivity, which could then significantly reverse impaired glucose tolerance (IGT), reports a study.

The use of methylphenidate in the treatment of children with attention-deficit/hyperactivity disorder (ADHD) does not contribute to an increased risk of nonaffective psychosis and may even confer protection against the risk, according to a study.

People who wish to quit vaping may find success with the help of varenicline, which has been found in a recent study to result in numerically higher abstinence rates relative to placebo.

Results from the 10-year follow-up of the HOST-EXAM* trial favour clopidogrel over aspirin as chronic maintenance therapy after percutaneous coronary intervention (PCI) with a drug-eluting stent (DES).

The conicity index (C-index) appears to be the most robust and most consistent prognostic value among adiposity indices in anticoagulated patients with atrial fibrillation (AF), suggests a study.

Initiation of an SGLT2 inhibitor, relative to a GLP-1 receptor agonist (RA), results in a lower risk of adverse kidney events among patients with stage 2 diabetes and stage 4‒5 chronic kidney disease (CKD), with similar cardiovascular and mortality risks, a study has shown.

The novel partial μ receptor agonist and full κ receptor antagonist ORP-101 has failed to demonstrate superiority to placebo in the treatment of patients with irritable bowel syndrome (IBS) with diarrhoea (IBS-D) in a phase II randomized controlled trial.